Stock results analysis for Industry - Biotechnology for Q2 FY25-26 ending Sep 30, 2025
Analysis of which stocks have performed the best and worst in Industry - Biotechnology for Q2 FY25-26 on the basis of sales/revenues, profits and profit margins. Only companies which have declared results in the current quarter are considered.
0
POSITIVE PROFIT GROWTH
1
NEGATIVE PROFIT GROWTH
0
NEUTRAL PROFIT GROWTH
-56.1
%
TOTAL REVENUE GROWTH
-97.2
%
TOTAL EBIDT GROWTH
-97.1
%
TOTAL OPER. PROFIT GROWTH
Positive
Negative
Pending
| Stock | Last Result Updated | Market Capitalization | Current Price | Operating Revenue Qtr | Revenue Growth Qtr YoY % | Revenue Surprise Qtr % | Net Profit Qtr | Net Profit Qtr Growth YoY % | Net Profit Surprise Qtr % | Operating Profit Qtr | Operating Profit Growth Qtr YoY % | EBITDA Qtr | EBITDA Qtr growth YoY % | Operating Profit Margin Qtr % | Operating Profit Qtr Margin% YoY Change |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Genomic Valley Biotech | 15-Oct-2025 |
9.46
|
30.98
|
0.09
|
-56.10
|
-
|
0.00
|
-97.76
|
-
|
0.00
|
-97.10
|
0.00
|
-97.24
|
4.56
|
-64.40
|
